@DoutorMaravilha Eficaz pra caralho! Confia!https://t.co/gJrEmVXd7Z. https://t.co/6WhiWfuTxB
@FlorianBonke Wenn man den Cochrane Bericht dazu anschaut, relativiert sich das Ganze. Die meisten Daten liegen beispielsweise großteils nur für Ungeimpfte vor. https://t.co/jnDiV1cLd0
@Catheri86517517 @CCCastera Efficacité vérifiée par RCT et études en vie réelle (https://t.co/znEkq4CRza) avec bonne tolérance (https://t.co/kNLmzqar57). Ne pas confondre avec le Remdesivir qui a un SMR et une ASMR médiocres.
RT @sudokuvariante: Popp et al. https://t.co/kJxYsislvJ argue that treatment with antivirals like ivermectin should start "within A MEAN of…
Then, treatment delay issue is not adequately assessed. https://t.co/YW0buLress
RT @sudokuvariante: Popp et al. https://t.co/kJxYsislvJ argue that treatment with antivirals like ivermectin should start "within A MEAN of…
Popp et al. https://t.co/kJxYsislvJ argue that treatment with antivirals like ivermectin should start "within A MEAN of 5 days after symptom onset" while Reis et al. https://t.co/uk2nSYrTO8 (the same team) remind that paxlovid must be prescribed within 5 d
@lonelysolipsist @dbdugger Oral nirmatrelvir/ritonavir (Paxlovid®) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms. [Note RITONAVIR component.] https://t.co/3R9fntuDWB
RT @mintimetz: What´s the new evidence base (RCTs) for Paxlovid (nirmatrelvir/ritonavir) for COVID19? #LivingSystematicReview While the Co…
RT @mintimetz: What´s the new evidence base (RCTs) for Paxlovid (nirmatrelvir/ritonavir) for COVID19? #LivingSystematicReview While the Co…
What´s the new evidence base (RCTs) for Paxlovid (nirmatrelvir/ritonavir) for COVID19? #LivingSystematicReview While the Cochrane review update (https://t.co/Eu7G6LnItG) is in preparation, you can check our regular study surveillance on #OSF. https://t.c
@VirtueOfNothing @First10EM GRADE recommendations were used in a Cochrain review. It found only low‐certainty evidence for the clinical benefits: https://t.co/YraTQv6LeU
RT @DrGRuralMD: @HeyNurseKat @MeganOlimpio @GSostakas @doritmi @stkirsch I have a study! https://t.co/hVLQxQXti6
@HeyNurseKat @MeganOlimpio @GSostakas @doritmi @stkirsch I have a study! https://t.co/hVLQxQXti6
@lebon80 @Apoo52105617 @MrUrben No need the sup IC >1. In case of statistical significance, juste downgrade the certainty of evidence. https://t.co/PTwKzmkPKq
RT @sudokuvariante: Medical recommendations: How to fraud [expert level]. Lesson 17: Use double standard to downgrade certainty of evidence…
RT @sudokuvariante: Medical recommendations: How to fraud [expert level]. Lesson 17: Use double standard to downgrade certainty of evidence…
RT @sudokuvariante: Medical recommendations: How to fraud [expert level]. Lesson 17: Use double standard to downgrade certainty of evidence…
Medical recommendations: How to fraud [expert level]. Lesson 17: Use double standard to downgrade certainty of evidence: 1/ https://t.co/LkhwiqBZsK 2/ https://t.co/uk2nSYrTO8 1/n
Pour les données d'essais randomisés à haut niveau de preuve, cf revue @cochrane Chez non-vaccinés à haut risque, Paxlovid pris en traitement précoce ↘ risque de mortalité - niveau de confiance faible https://t.co/q9PGmQKkMI https://t.co/Up2IuG2CLo
@ifihadastick @JordanSchachtel @AlexBerenson Not only that but the single RCT is low quality evidence, with majority <65 (classic pharma avoiding those that would benefit most) & why are placebo/standard treatment discontinuing so much? How do the 2
Nirmatrelvir combinado com ritonavir para prevenir e tratar a COVID‐19 - Reis, S - 2022 | Cochrane Library https://t.co/uaEgOpyF3J
Links to 1. the Cochrane Review implementing the process: https://t.co/0YYJM7DXnr 2. the latest surveillance data on #OSF: https://t.co/wGUEc9srg6 (2/2) https://t.co/cJLW8eQDfn
RT @CochraneJapan: ニルマトレルビルとリトナビルの併用は新型コロナウイルス感染症の治療または予防に有効か https://t.co/3vkvuBzcxa
RT @CochraneJapan: ニルマトレルビルとリトナビルの併用は新型コロナウイルス感染症の治療または予防に有効か https://t.co/3vkvuBzcxa
ニルマトレルビルとリトナビルの併用は新型コロナウイルス感染症の治療または予防に有効か https://t.co/3vkvuBzcxa
RT @mintimetz: We updated our monthly search for the Cochrane #LivingSystematicReview on #Paxlovid (nirmatrelvir/ritonavir). 3 new ongoing…
RT @mintimetz: We updated our monthly search for the Cochrane #LivingSystematicReview on #Paxlovid (nirmatrelvir/ritonavir). 3 new ongoing…
RT @mintimetz: We updated our monthly search for the Cochrane #LivingSystematicReview on #Paxlovid (nirmatrelvir/ritonavir). 3 new ongoing…
RT @mintimetz: We updated our monthly search for the Cochrane #LivingSystematicReview on #Paxlovid (nirmatrelvir/ritonavir). 3 new ongoing…
We updated our monthly search for the Cochrane #LivingSystematicReview on #Paxlovid (nirmatrelvir/ritonavir). 3 new ongoing trials identified (11 ongoing total). Latest surveillance data fully transparent on #OSF: https://t.co/wGUEc9srg6 Link to review:
@akbefring @Hokkis Pfizers første RCT på UVAKSINERTE pasienter (EPIC-HR) med HØY RISK (80% overvektige, 40% røyk), viste effekt. Cochrane: "There is low‐certainty evidence that nirmatrelvir/ritonavir reduces the risk of all‐cause mortality(...)" https://t.
RT @Roses_Parker: #Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 Read the new @CochraneLibrary Clinical Answe…
RT @Roses_Parker: #Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 Read the new @CochraneLibrary Clinical Answe…
#Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 Read the new @CochraneLibrary Clinical Answer: https://t.co/wyqwTnKlA1 Read the plain language summary and full review: https://t.co/K7MIUmwfK6 #CochraneClinicalAnswers
RT @CochraneNursing: Is nirmatrelvir/ritonavir (Paxlovid®) effective for treating #COVID19 in outpatient settings with asymptomatic or mild…
RT @CochraneNursing: Is nirmatrelvir/ritonavir (Paxlovid®) effective for treating #COVID19 in outpatient settings with asymptomatic or mild…
RT @CochraneNursing: Is nirmatrelvir/ritonavir (Paxlovid®) effective for treating #COVID19 in outpatient settings with asymptomatic or mild…
RT @CochraneNursing: Is nirmatrelvir/ritonavir (Paxlovid®) effective for treating #COVID19 in outpatient settings with asymptomatic or mild…
Is nirmatrelvir/ritonavir (Paxlovid®) effective for treating #COVID19 in outpatient settings with asymptomatic or mild disease? See the latest evidence from a #living #systematicreview with continuous monitoring of new and ongoing studies👉🏾https://t.co/Qz3
RT @CochraneLibrary: #Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 ➡️ Read the new @CochraneLibrary Clinical…
RT @CochraneLibrary: #Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 ➡️ Read the new @CochraneLibrary Clinical…
RT @CochraneLibrary: #Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 ➡️ Read the new @CochraneLibrary Clinical…
#Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 ➡️ Read the new @CochraneLibrary Clinical Answer: https://t.co/dU8fs8bRug 📃 Read the plain language summary and full review: https://t.co/gy9tPLRaSx #CochraneClinicalAnswers htt
New Cochrane review: Is the combination nirmatrelvir plus ritonavir effective for treating or preventing COVID-19? https://t.co/qGtB9vNDnH https://t.co/CQf5cqbmAJ
RT @CochraneIberoam: ¿La combinación de nirmatrelvir más ritonavir es eficaz para tratar o prevenir la covid‐19? La confianza en la eviden…
RT @CochraneIberoam: ¿La combinación de nirmatrelvir más ritonavir es eficaz para tratar o prevenir la covid‐19? La confianza en la eviden…
¿La combinación de nirmatrelvir más ritonavir es eficaz para tratar o prevenir la covid‐19? La confianza en la evidencia es de baja a moderada porque sólo fue posible incluir un estudio, concluye esta revisión @Cochrane_IDG recién salida del horno: https
RT @CochraneLibrary: 💊💊 Is the combination #nirmatrelvir plus #ritonavir effective for treating or preventing #COVID19? 📚 New #openaccess…
RT @CochraneLibrary: 💊💊 Is the combination #nirmatrelvir plus #ritonavir effective for treating or preventing #COVID19? 📚 New #openaccess…
Is the combination nirmatrelvir plus ritonavir effective for treating or preventing COVID-19? Read the review at: https://t.co/RyCishlTdn @CochraneAfrica @cochranecollab @CochraneLibrary
RT @COVID_Evidence: PubMed: Nirmatrelvir combined with ritonavir for preventing and treating COVID-19: BACKGROUND: Oral nirmatrelvir/riton…
Is the combination nirmatrelvir plus ritonavir effective for treating or preventing COVID-19? | Cochrane https://t.co/rthFiP1zhM
Link to the full review: https://t.co/roYbTKT1uQ This is the first #CochraneReview to transparently report the living evidence #surveillance process that occurs between published versions of the #LivingSystematicReview.
💊💊 Is the combination #nirmatrelvir plus #ritonavir effective for treating or preventing #COVID19? 📚 New #openaccess review by @Cochrane_IDG looks at the latest evidence. https://t.co/gy9tPLRaSx https://t.co/APFL1HybJ2
(Cochrane) Nirmatrelvir/ritonavir para la prevención y tratamiento de la COVID19: baja certeza de su papel en reducir el riesgo a gravedad con los estudios actuales. En espera de resultados de estudios en marcha. https://t.co/J8ryDkRpKE
PubMed: Nirmatrelvir combined with ritonavir for preventing and treating COVID-19: BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid®) aims to avoid severe COVID-19 in asymptomatic people or those with mild symptoms,… https://t.co/Iysv4iLg6L #covid19 #SAR
RT @Cochrane_IDG: New @Cochrane_IDG review published: Nirmatrelvir combined with ritonavir for preventing and treating #COVID‐19 Access t…
New @Cochrane_IDG review published: Nirmatrelvir combined with ritonavir for preventing and treating #COVID‐19 Access the full-text open access review here: https://t.co/qN0ngrXK8G https://t.co/tSEGpYxedN